You’ve tried medication after medication. You’ve committed to therapy. You’ve done everything your doctors have recommended, yet the weight of treatment-resistant depression still hasn’t lifted. If this sounds familiar, you’re not alone—about one-third of people with major depression don’t respond adequately to traditional antidepressants. But here’s something worth knowing: patients right here in San Diego are finding breakthrough relief with Spravato treatment, often experiencing improvements within hours rather than the weeks or months typical of conventional medications.
At Resilience Integrative Wellness, we’ve witnessed countless transformations through our FDA-approved Spravato program. Located at 6719 Alvarado Road, Suite 201 in San Diego, our veteran-owned clinic combines cutting-edge treatment with the compassionate, personalized care you deserve. Let’s explore what real patients are experiencing with Spravato results in San Diego and why this innovative therapy is changing lives throughout Southern California.
Understanding What Makes Spravato Different
Spravato isn’t just another antidepressant. This FDA-approved nasal spray contains esketamine, a medication that works through your brain’s glutamate system rather than the traditional serotonin pathways targeted by most antidepressants. Think of it like taking a completely different route when the main highway is blocked—sometimes you need an alternative path to reach your destination.
What makes this particularly remarkable is the speed. While conventional antidepressants might take six to eight weeks to show benefits, many Spravato patients notice meaningful improvements within 24 hours of their first treatment. Clinical trials have demonstrated that esketamine produces rapid and clinically significant reductions in depressive symptoms, with remission rates ranging from 27% to 50% across multiple studies.
The mechanism behind this rapid relief involves promoting neuroplasticity—your brain’s ability to form new neural connections and pathways. Research shows that Spravato stimulates brain-derived neurotrophic factor, essentially helping your brain “rewire” the dysfunctional circuits associated with depression. This unique approach explains why patients who haven’t responded to multiple traditional medications often find success with Spravato.
Real Transformations: What San Diego Patients Are Experiencing
The most compelling evidence for any treatment comes from the people it helps. Across our San Diego clinic and throughout clinical research, patients share remarkably consistent stories of transformation after beginning Spravato therapy.
Jennifer’s story reflects what we hear regularly. After struggling with severe depression for over a decade and cycling through eight different antidepressants with minimal improvement, she’d nearly given up hope. “My first Spravato treatment was truly life-changing,” she shares. “Within hours, I felt a lightness I hadn’t experienced in years. The compassionate care and follow-up support helped me maintain these improvements. For the first time in years, I feel hopeful about my future.”
Michael’s experience highlights another common pattern. When his depression became treatment-resistant despite his psychiatrist’s best efforts, Spravato offered a new possibility. “The team was professional and caring from my first call. After completing the initial series of treatments, my depression symptoms decreased dramatically. I’m now on a maintenance program that’s allowed me to return to work and enjoy my family again. The difference is night and day.”
These aren’t isolated cases. Research from the TRANSFORM-2 trial demonstrated that patients receiving Spravato plus an oral antidepressant showed statistically significant reductions in depression scores compared to those receiving placebo plus an antidepressant. The mean difference of 4.0 points on the Montgomery-Åsberg Depression Rating Scale represented clinically meaningful improvement that patients could actually feel in their daily lives.
What’s particularly encouraging is the sustained benefit. The SUSTAIN-1 trial focused on relapse prevention and found that patients who continued Spravato treatment were 51% less likely to experience relapse compared to those who discontinued. For people who’ve spent years battling treatment-resistant depression, this sustained relief represents something precious: stability and the ability to plan for a future without constant fear of the next depressive episode.
The Science Behind the Success
Understanding why Spravato works helps explain the remarkable results patients are experiencing. Traditional antidepressants primarily influence serotonin and norepinephrine, neurotransmitters that regulate mood. However, for about one-third of people with depression, this approach simply doesn’t provide adequate relief—their brain chemistry might need a different intervention.
Spravato targets the glutamate system through NMDA receptor antagonism. Glutamate is your brain’s most abundant excitatory neurotransmitter, playing crucial roles in learning, memory, and neural plasticity. When Spravato blocks certain NMDA receptors, it triggers a cascade of effects that ultimately promote the growth of new neural connections in brain regions affected by depression.
This process happens remarkably fast. Within hours of administration, Spravato increases levels of brain-derived neurotrophic factor, a protein that supports neuron survival and growth. Think of it as fertilizer for your brain’s neural networks, encouraging healthy new connections to form while strengthening existing beneficial pathways.
Research published in major psychiatric journals confirms these effects extend beyond brain chemistry. Studies using advanced neuroimaging have shown that esketamine treatment is associated with increased connectivity in brain regions critical for mood regulation, including the prefrontal cortex and anterior cingulate cortex. These structural and functional changes help explain why patients experience such rapid and sustained improvements.
The ASPIRE I and II trials further demonstrated Spravato’s unique capabilities. These studies examined patients with major depressive disorder and active suicidal ideation—arguably the most severe and urgent form of depression. Both trials showed statistically significant improvements in depression scores within just 24 hours of the first dose, offering hope to patients in acute distress when every hour matters.
What the Treatment Journey Actually Looks Like
Walking into our San Diego clinic for Spravato treatment might feel intimidating at first, but understanding the process helps ease those concerns. The entire experience is designed around your safety, comfort, and therapeutic success.
Your journey begins with a comprehensive evaluation. Our medical team reviews your treatment history, current symptoms, and overall health to determine if you’re a good candidate for Spravato. The FDA has approved Spravato specifically for treatment-resistant depression, meaning you’ll need to demonstrate that you’ve tried and not adequately responded to at least two different antidepressants.
On treatment days, you’ll arrive at our clinic where you’ll self-administer the nasal spray under our direct supervision. The process is straightforward—you’ll use one or more pre-filled devices, with a brief rest period between each if multiple devices are needed. Most patients start with 56mg and may adjust to 84mg based on their response and tolerability.
Here’s what makes Spravato unique: you must remain at our clinic for at least two hours after administration. This isn’t just a precaution—it’s a crucial part of the treatment protocol. Spravato can cause temporary dissociation, dizziness, and sedation, which typically peak around 40 minutes after administration and resolve within two hours. During this monitoring period, you’ll relax in one of our comfortable private treatment rooms, complete with luxury reclining chairs, Bose headphones, soft blankets, and complimentary refreshments.
The treatment schedule is intensive at first but becomes less frequent over time. You’ll typically start with twice-weekly sessions for the first month, move to weekly sessions during the second month, and then transition to weekly or bi-weekly maintenance treatments based on your individual response. This gradual reduction allows your brain to stabilize at your optimal treatment frequency.
Why Insurance Coverage Changes Everything
One of Spravato’s most significant advantages over other innovative treatments is insurance coverage. Unlike IV ketamine therapy, which is typically considered off-label and rarely covered by insurance, Spravato has FDA approval specifically for treatment-resistant depression. This approval means most major insurance plans include Spravato in their formularies, making breakthrough treatment accessible to far more people.
The coverage process requires prior authorization, which sounds complicated but becomes manageable with experienced support. Our team at Resilience Integrative Wellness has extensive expertise navigating insurance requirements for Spravato. We’ll verify your benefits, obtain necessary authorizations, and handle the administrative details so you can focus on what matters: getting better.
Your insurance company will typically require documentation showing you’ve tried and not adequately responded to at least two different antidepressants during your current depressive episode. You’ll also need to use Spravato in conjunction with an oral antidepressant as part of the FDA-approved protocol. These requirements are built into the treatment framework to ensure appropriate patient selection and maximize the likelihood of successful outcomes.
For patients with high deductibles or limited coverage, we offer flexible payment options and healthcare financing to make treatment accessible. We believe everyone who could benefit from Spravato deserves the opportunity to try it, regardless of their financial situation.
Comparing Results: Spravato Versus Traditional Approaches
The contrast between Spravato outcomes and traditional antidepressant results is striking. Let’s look at what research and real-world experience tell us.
Speed of relief represents perhaps the most dramatic difference. Traditional antidepressants typically require four to eight weeks before patients notice meaningful improvement, with full benefits sometimes taking three months or longer. Spravato, by contrast, often produces noticeable improvements within 24 hours. For someone in the depths of treatment-resistant depression, the difference between waiting months and seeing results in hours can be life-changing—sometimes literally.
Remission rates tell another compelling story. In the general population treated with first-line antidepressants, remission rates hover around 30-40%. For people with treatment-resistant depression who’ve already failed multiple medications, traditional treatment success rates drop even further. Spravato clinical trials have demonstrated remission rates up to 50% in treatment-resistant populations—people who’ve already proven difficult to treat with conventional approaches.
The SUSTAIN-1 study provided particularly impressive long-term data. Among patients who achieved remission or response during acute Spravato treatment, continuing the medication significantly delayed relapse compared to stopping. The hazard ratio of 0.49 means patients on continued Spravato therapy were roughly half as likely to relapse—a substantial protective effect that translates to sustained quality of life improvements.
Recent research published in JAMA Psychiatry examined Spravato as monotherapy—used alone without a concurrent oral antidepressant. Both 56mg and 84mg doses demonstrated statistically significant and clinically meaningful improvements compared to placebo, with results appearing within 24 hours and maintaining through day 28. This finding is particularly relevant for patients who experience intolerable side effects from oral antidepressants or who haven’t responded despite adequate trials of multiple medications.
Safety Considerations and What to Expect
Every medical treatment involves balancing potential benefits against possible risks. Spravato’s safety profile, established through extensive clinical trials and real-world use, shows it’s generally well-tolerated when administered properly in certified healthcare settings.
The most common side effects are temporary and typically resolve within the two-hour monitoring period. Dissociation—feeling disconnected from your thoughts, feelings, or surroundings—affects roughly 30% of patients and usually peaks around 40 minutes after administration. While this can feel unsettling, most patients report the sensation decreases with repeated treatments as their bodies acclimate.
Other frequent temporary effects include dizziness, nausea, headache, and fatigue. Blood pressure often increases temporarily, which is why we continuously monitor your vital signs during the observation period. These effects are why you cannot drive or operate machinery until the next day after receiving Spravato—you must arrange for someone to drive you home after each treatment session.
Spravato isn’t appropriate for everyone. You shouldn’t use it if you have uncontrolled high blood pressure, history of brain aneurysm or bleeding, active substance abuse issues, or if you’re pregnant or breastfeeding. Certain heart conditions may also be contraindications. During your consultation, our medical team thoroughly reviews your health history to ensure Spravato is safe for your specific situation.
The FDA requires Spravato administration through a Risk Evaluation and Mitigation Strategy program, meaning treatment can only occur in certified healthcare facilities with trained providers. While this creates logistical requirements, it also ensures consistent safety standards and appropriate medical supervision. At Resilience Integrative Wellness, our 60 years of combined medical experience means you’re in expert hands throughout your treatment journey.
The Resilience Difference: Why San Diego Patients Choose Us
Success with Spravato treatment depends not just on the medication itself but on the expertise and care surrounding it. Our San Diego clinic stands out for several reasons that directly impact your treatment outcomes and experience.
We’re veteran-owned and operated, bringing deep understanding of trauma, PTSD, and the unique mental health challenges faced by service members and their families. This background informs our trauma-informed care approach, ensuring you feel safe and understood throughout your treatment journey—especially important for patients whose treatment-resistant depression stems from traumatic experiences.
Our facility features six private treatment rooms designed for your comfort during the monitoring period. You’ll find luxury reclining chairs, Bose headphones for relaxation or entertainment, warm blankets, and complimentary refreshments. The environment matters when you’re spending two hours at a clinic twice weekly—we’ve created a space that feels more like a wellness retreat than a medical office.
With 60 years of combined medical experience, our clinical team brings extensive expertise in administering Spravato and monitoring patient responses. This experience translates to nuanced care—recognizing subtle signs that might indicate dosage adjustments, identifying when additional support might help, and seamlessly coordinating with your other healthcare providers for comprehensive treatment.
We offer flexible financing options because we believe financial barriers shouldn’t prevent you from accessing life-changing treatment. Insurance navigation can be complex, but our team’s experience with prior authorization processes and benefit verification means you’ll have clear answers about coverage and out-of-pocket costs before beginning treatment.
Perhaps most importantly, we achieve an 80% success rate with our treatments. This track record reflects both the effectiveness of Spravato itself and the comprehensive, personalized approach we take with every patient. You’re not just receiving a medication—you’re gaining a partner committed to your recovery and long-term wellness.
Beyond Individual Stories: What the Research Shows
While personal testimonials powerfully illustrate Spravato’s impact, the scientific evidence provides essential context for understanding what results you might realistically expect.
A comprehensive analysis of multiple Phase 3 trials found that Spravato produced rapid and clinically meaningful improvements in depressive symptoms, with benefits emerging within hours of the first dose and maintaining throughout treatment. The consistency across different trials and patient populations strengthens confidence that these results generalize beyond any single study.
The TRANSFORM-2 trial stands out for its rigorous design. Researchers compared Spravato plus a newly initiated oral antidepressant against placebo plus the same oral antidepressant in patients with treatment-resistant depression. By day 28, the Spravato group showed a 4.0-point greater reduction on the Montgomery-Åsberg Depression Rating Scale—a difference that patients could feel in their daily functioning and quality of life.
Long-term safety data from the SUSTAIN-3 study provides reassurance about extended Spravato use. With mean treatment duration of 31.5 months and some patients continuing for up to 56 months, the trial demonstrated sustained efficacy and acceptable tolerability. Notably, 76% of participants remained in the study for two years or longer—remarkable retention suggesting patients found meaningful benefit that outweighed the inconvenience of regular clinic visits.
The ASPIRE trials examined perhaps the most critical question: Can Spravato help people with active suicidal ideation? Both ASPIRE I and II demonstrated statistically significant improvements in depression scores within 24 hours, though they didn’t show superiority over placebo specifically for preventing suicide attempts. This finding suggests Spravato can provide rapid relief from the crushing weight of severe depression, potentially creating a crucial window for other interventions to take effect.
Recent publications in prestigious journals like JAMA Psychiatry continue expanding our understanding of Spravato’s applications. A 2025 study examining esketamine monotherapy found that both 56mg and 84mg doses produced significant benefits compared to placebo, with effects appearing within 24 hours and maintaining through four weeks. For patients who’ve struggled with medication side effects, this evidence that Spravato can work effectively on its own represents an important additional option.
Taking the First Step Toward Relief
If you’re reading this and seeing yourself in these stories—years of treatment-resistant depression, medication after medication that hasn’t worked, diminishing hope—it’s time to explore whether Spravato might be right for you. The patients whose transformations we’ve shared weren’t fundamentally different from you before they started treatment. They were simply tired of suffering and willing to try something new.
Your first step is scheduling a free consultation with our team at Resilience Integrative Wellness. During this conversation, we’ll discuss your symptoms, treatment history, and goals. We’ll answer your questions about Spravato, explain what to expect, and determine whether you’re a good candidate based on FDA criteria. There’s no pressure—just honest, compassionate guidance about your options.
If we agree that Spravato is worth pursuing, we’ll conduct a thorough medical evaluation and begin the insurance verification process. Our team will handle the prior authorization requirements, communicate with your insurance provider, and give you clear information about coverage and costs before you commit to treatment.
Once approved, we’ll schedule your first session and provide detailed preparation instructions. You’ll know exactly what to bring, how to prepare, and what to expect during and after treatment. Throughout your Spravato journey, our clinical team remains available to address concerns, adjust treatment as needed, and celebrate your progress.
Don’t let treatment-resistant depression control another day of your life. The Spravato results San Diego patients are experiencing aren’t limited to a lucky few—they represent a breakthrough treatment option that could work for you. Real relief is possible, often within hours of your first treatment.
Frequently Asked Questions
How quickly will I notice results from Spravato?
Many patients report noticeable improvements within hours of their first treatment, with significant symptom reduction often occurring within the first few sessions. Clinical trials showed improvements appearing within 24 hours, though individual responses vary. Unlike traditional antidepressants that take weeks to work, Spravato’s rapid action is one of its most valuable benefits for people suffering from severe treatment-resistant depression.
What does Spravato cost and does insurance typically cover it?
Most major insurance plans cover Spravato for FDA-approved indications like treatment-resistant depression. Coverage typically requires prior authorization and documentation of previous treatment failures. Our team will verify your specific benefits and guide you through the approval process to maximize your coverage and minimize out-of-pocket costs.
Can I drive myself home after Spravato treatment?
No, you cannot drive or operate machinery until the next day after receiving Spravato. You must arrange for someone to drive you home after each treatment session. This safety requirement exists because Spravato can cause temporary dissociation, dizziness, and sedation that make driving dangerous even after the two-hour monitoring period.
How many Spravato treatments will I need to see results?
The typical protocol includes twice-weekly treatments for the first month, weekly treatments in the second month, and then weekly or bi-weekly maintenance treatments based on your response. Many patients notice improvements after just a few sessions, but the full treatment protocol helps establish and maintain those improvements over time. Your specific schedule will be customized to your individual needs and response.
What are the common side effects of Spravato?
Common temporary side effects include dissociation, dizziness, nausea, fatigue, and headache. These effects typically resolve within one to two hours and are closely monitored by our medical team throughout your treatment. Most patients find the temporary side effects are far outweighed by the relief from their depression symptoms.
How is Spravato different from ketamine infusions?
Spravato is FDA-approved specifically for treatment-resistant depression and is often covered by insurance, while ketamine infusions are used off-label and typically aren’t covered. Spravato is self-administered as a nasal spray, while ketamine requires IV infusion. Both work through similar mechanisms but have different administration routes, dosing protocols, and coverage considerations.
Do I need to stop my current antidepressants to try Spravato?
No, Spravato is designed to be used alongside an oral antidepressant as part of the FDA-approved treatment protocol. You should continue your current medications unless specifically directed otherwise by your healthcare provider. The combination approach often produces better results than either treatment alone.
What happens if Spravato doesn’t work for me?
If you don’t respond adequately to Spravato, we can explore other innovative treatment options including IV ketamine therapy or TMS therapy. Not every treatment works for every person, but we’re committed to helping you find the most effective approach for your specific situation. Our comprehensive treatment offerings mean we can adjust your care plan based on your response.
Your Next Step Toward Healing
Don’t let treatment-resistant depression control your life any longer. At Resilience Integrative Wellness, we’re here to help you find the breakthrough relief you’ve been searching for. Our San Diego clinic specializes in Spravato treatment for patients who haven’t responded adequately to traditional antidepressants, offering FDA-approved care with compassionate, personalized support.
Ready to learn more about Spravato results San Diego patients are experiencing? Contact us today to schedule your free consultation. We’ll answer your questions, review your treatment history, and help determine if Spravato is right for you.
Resilience Integrative Wellness
6719 Alvarado Road, Suite 201
San Diego, CA 92120
(619) 768-8723
Schedule Your Free Consultation
Check out our testimonials page to hear more success stories from real San Diego patients who’ve found relief through our innovative treatments.
The information on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Always consult with a qualified healthcare provider before beginning any new treatment. Spravato (esketamine) is a prescription medication that must be administered in certified healthcare settings under medical supervision. Treatment-resistant depression is defined as inadequate response to at least two different antidepressants during the current depressive episode.
